JP2012529021A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012529021A5 JP2012529021A5 JP2012513606A JP2012513606A JP2012529021A5 JP 2012529021 A5 JP2012529021 A5 JP 2012529021A5 JP 2012513606 A JP2012513606 A JP 2012513606A JP 2012513606 A JP2012513606 A JP 2012513606A JP 2012529021 A5 JP2012529021 A5 JP 2012529021A5
- Authority
- JP
- Japan
- Prior art keywords
- therapy
- prostate cancer
- subject
- benefit
- side effects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010060862 Prostate cancer Diseases 0.000 description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 238000012544 monitoring process Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 238000001794 hormone therapy Methods 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09161956 | 2009-06-04 | ||
| EP09161956.9 | 2009-06-04 | ||
| PCT/EP2010/057680 WO2010139711A1 (en) | 2009-06-04 | 2010-06-02 | Means and methods for diagnosing prostate carcinomas |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016092246A Division JP6427137B2 (ja) | 2009-06-04 | 2016-05-02 | 前立腺癌を診断する手段と方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012529021A JP2012529021A (ja) | 2012-11-15 |
| JP2012529021A5 true JP2012529021A5 (cg-RX-API-DMAC7.html) | 2013-07-18 |
| JP5933432B2 JP5933432B2 (ja) | 2016-06-08 |
Family
ID=42320338
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012513606A Expired - Fee Related JP5933432B2 (ja) | 2009-06-04 | 2010-06-02 | 前立腺癌を診断する手段と方法 |
| JP2016092246A Expired - Fee Related JP6427137B2 (ja) | 2009-06-04 | 2016-05-02 | 前立腺癌を診断する手段と方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016092246A Expired - Fee Related JP6427137B2 (ja) | 2009-06-04 | 2016-05-02 | 前立腺癌を診断する手段と方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20120122243A1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2804001B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5933432B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102483416A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2764049A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE112010002253T5 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2516866T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2438445T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010139711A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101821551B1 (ko) | 2008-06-20 | 2018-01-25 | 아지노모토 가부시키가이샤 | 전립선 질환의 평가 방법 |
| EP3502707A1 (en) | 2010-01-29 | 2019-06-26 | metanomics GmbH | Means and methods for diagnosing heart failure in a subject |
| MX362555B (es) | 2012-03-05 | 2019-01-24 | Oy Arctic Partners Ab | Metodos y aparatos para predecir riesgo de cancer de prostata y volumen de glandula prostatica. |
| ES2688121T3 (es) * | 2012-10-02 | 2018-10-31 | Metanomics Health Gmbh | Medios y procedimientos de diagnóstico de la reaparición de cáncer de próstata después de prostatectomía |
| JP2014169955A (ja) * | 2013-03-05 | 2014-09-18 | Seiko Epson Corp | 分析装置、分析方法、これらに用いる光学素子および電子機器、並びに光学素子の設計方法 |
| JP6201369B2 (ja) * | 2013-03-28 | 2017-09-27 | セイコーエプソン株式会社 | 検出装置及び電子機器 |
| ES2534732B1 (es) * | 2013-08-05 | 2016-04-21 | Servicio Andaluz De Salud | Método de clasificación, diagnóstico y seguimiento de individuos con riesgo de padecer cáncer de pulmón mediante el análisis de sudor |
| JP6222629B2 (ja) * | 2013-08-29 | 2017-11-01 | 花王株式会社 | 排尿障害のバイオマーカー |
| JP2015055482A (ja) * | 2013-09-10 | 2015-03-23 | セイコーエプソン株式会社 | 分析装置、分析方法、これらに用いる光学素子及び電子機器 |
| KR101838133B1 (ko) | 2013-10-04 | 2018-03-14 | 주식회사 씨스퀘어 | 사르코신 대사산물 중 포름알데히드를 이용한 전립선암 진단 시험지, 그 제조 방법 및 이를 이용한 전립선암 진단에 필요한 정보를 제공하는 방법 |
| GB201322034D0 (en) * | 2013-12-12 | 2014-01-29 | Almac Diagnostics Ltd | Prostate cancer classification |
| US10274496B2 (en) | 2014-01-17 | 2019-04-30 | University Of Washington | Biomarkers for detecting and monitoring colon cancer |
| CN106415274A (zh) * | 2014-03-26 | 2017-02-15 | 梅坦诺米克斯保健有限公司 | 基于代谢物组的血液样本质量的测定方法和手段 |
| WO2015148979A1 (en) * | 2014-03-28 | 2015-10-01 | Opko Diagnostics, Llc | Compositons and methods related to diagnosis of prostate cancer |
| US12326453B2 (en) | 2014-03-28 | 2025-06-10 | Opko Diagnostics, Llc | Compositions and methods for active surveillance of prostate cancer |
| JP5796863B1 (ja) * | 2014-10-31 | 2015-10-21 | 節郎 山田 | 腫瘍検査用組成物及び腫瘍検査用試験紙 |
| CN104614462B (zh) * | 2015-02-11 | 2016-09-14 | 中国人民解放军第四军医大学 | 一种高原肺水肿诊断标志物及其应用和诊断试剂盒 |
| ES2867798T3 (es) | 2015-03-27 | 2021-10-20 | Opko Diagnostics Llc | Estándares del antígeno prostático y usos de estos |
| EP3229026A1 (en) * | 2016-04-06 | 2017-10-11 | Universite De Bordeaux | Biomarkers for the diagnosis of inflammation-related diseases |
| ES2953498T3 (es) * | 2016-06-02 | 2023-11-13 | Metabolon Inc | Método de espectrometría de masas para la detección y cuantificación de metabolitos |
| CN110476066A (zh) * | 2017-03-31 | 2019-11-19 | 学校法人庆应义塾 | 并用抗癌剂的感受性判定标记 |
| CN107589196B (zh) * | 2017-11-02 | 2019-09-20 | 浙江高美生物科技有限公司 | 一种预示肺癌脑转移的小分子标志物及在诊断方面的应用 |
| CN108362804B (zh) * | 2018-02-27 | 2019-01-29 | 山东英盛生物技术有限公司 | 一种检测血液样品中dha含量的方法及试剂盒 |
| EP4045905A4 (en) * | 2019-10-17 | 2023-10-11 | Biomark Cancer Systems Inc. | METHOD FOR DIAGNOSIS OF NON-SMALL CELL LUNG CANCER AT EARLY STAGE |
| CN110749732B (zh) * | 2019-11-27 | 2021-10-15 | 中南大学 | 诊断多发性骨髓瘤的血液代谢物标志物及应用 |
| US20210333280A1 (en) * | 2020-04-23 | 2021-10-28 | YatHing Biotechnology Company Limited | Methods related to the diagnosis of prostate cancer |
| CN111721751A (zh) * | 2020-06-30 | 2020-09-29 | 四川大学华西医院 | 一种检测结直肠恶性肿瘤的装置 |
| WO2022011093A1 (en) * | 2020-07-08 | 2022-01-13 | Board Of Regents, The University Of Texas System | Methods for the detection and treatment of prostate cancer |
| CN111999404A (zh) * | 2020-08-14 | 2020-11-27 | 中元伯瑞生物科技(珠海横琴)有限公司 | 神经酸在制备甲状腺恶性肿瘤的检测试剂中的应用 |
| CN112748195A (zh) * | 2020-12-23 | 2021-05-04 | 沈阳农业大学 | 一种利用gc-nci-ms对脂肪酸、氨基酸和多官能团有机酸同时检测的方法 |
| CN112630363A (zh) * | 2020-12-31 | 2021-04-09 | 四川大学华西医院 | 一种MXene生物响应特性代谢组学分析方法 |
| CN114527222B (zh) * | 2022-02-22 | 2024-08-06 | 广州市番禺区中心医院 | 前列腺癌相关标志物及其应用 |
| AU2023331422A1 (en) * | 2022-09-02 | 2025-04-17 | Baker Heart and Diabetes Institute | Prognostic markers |
| TW202528739A (zh) * | 2023-09-05 | 2025-07-16 | 國立臺灣大學 | 用於前列腺癌的生物標記 |
| CN118091155B (zh) * | 2024-02-29 | 2025-02-18 | 汕头大学医学院第二附属医院 | 大肠癌代谢标志物及其在诊断大肠癌中的应用 |
| CN118604356A (zh) * | 2024-06-06 | 2024-09-06 | 温州医科大学 | 用于前列腺癌风险分层的无创诊断生物标志物组合及其应用 |
| CN119269471A (zh) * | 2024-09-19 | 2025-01-07 | 青岛大学 | 基于拉曼光谱的肿瘤细胞转移能力检测方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4540884A (en) | 1982-12-29 | 1985-09-10 | Finnigan Corporation | Method of mass analyzing a sample by use of a quadrupole ion trap |
| US5397894A (en) | 1993-05-28 | 1995-03-14 | Varian Associates, Inc. | Method of high mass resolution scanning of an ion trap mass spectrometer |
| WO2003073464A1 (de) | 2002-02-28 | 2003-09-04 | Metanomics Gmbh & Co. Kgaa | Massenspektrometrisches verfahren zur analyse von substanzgemischen |
| EP1862797A4 (en) * | 2005-03-16 | 2009-09-16 | Ajinomoto Kk | DEVICE, METHOD, SYSTEM AND PROGRAM FOR EVALUATING BIOLOGICAL STATES, DEVICE, METHOD AND PROGRAM FOR GENERATING AN EVALUATION FUNCTION AND RECORDING MEDIUM |
| US20070231822A1 (en) * | 2006-02-28 | 2007-10-04 | Michael Mitas | Methods for the detection and treatment of cancer |
| KR20090006837A (ko) * | 2006-03-24 | 2009-01-15 | 페노미넘 디스커버리스 인코포레이티드 | 전립선 암 진단용 생물표지자 및 그의 제조방법 |
| US8216848B2 (en) * | 2006-03-24 | 2012-07-10 | Metanomics Gmbh | Means and method for diagnosing diabetes |
| US20090075284A1 (en) * | 2006-09-19 | 2009-03-19 | The Regents Of The University Of Michigan | Metabolomic profiling of prostate cancer |
| WO2008036691A2 (en) * | 2006-09-19 | 2008-03-27 | Metabolon, Inc. | Biomarkers for prostate cancer and methods using the same |
| EP2597464B1 (en) * | 2007-08-16 | 2015-02-25 | The Regents of the University of Michigan | Metabolomic profiling of prostate cancer |
| US7989630B2 (en) * | 2008-04-30 | 2011-08-02 | National Institutes Of Health Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Radiotracers for imaging P-glycoprotein function |
| WO2009151967A1 (en) * | 2008-05-28 | 2009-12-17 | Georgia Tech Research Corporation | Metabolic biomarkers for ovarian cancer and methods of use thereof |
-
2010
- 2010-06-02 WO PCT/EP2010/057680 patent/WO2010139711A1/en not_active Ceased
- 2010-06-02 EP EP14170939.4A patent/EP2804001B1/en not_active Not-in-force
- 2010-06-02 US US13/375,534 patent/US20120122243A1/en not_active Abandoned
- 2010-06-02 ES ES10724454.3T patent/ES2516866T3/es active Active
- 2010-06-02 EP EP10724454.3A patent/EP2438445B1/en not_active Not-in-force
- 2010-06-02 DE DE112010002253T patent/DE112010002253T5/de not_active Withdrawn
- 2010-06-02 CA CA2764049A patent/CA2764049A1/en not_active Abandoned
- 2010-06-02 PL PL10724454T patent/PL2438445T3/pl unknown
- 2010-06-02 EP EP17182999.7A patent/EP3296743A1/en not_active Withdrawn
- 2010-06-02 CN CN2010800345524A patent/CN102483416A/zh active Pending
- 2010-06-02 JP JP2012513606A patent/JP5933432B2/ja not_active Expired - Fee Related
-
2016
- 2016-05-02 JP JP2016092246A patent/JP6427137B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012529021A5 (cg-RX-API-DMAC7.html) | ||
| Schaller et al. | Dual anti‐inflammatory and anti‐parasitic action of topical ivermectin 1% in papulopustular rosacea | |
| Martin et al. | Molecular mechanisms of cancer cachexia‐related loss of skeletal muscle mass: data analysis from preclinical and clinical studies | |
| Xu et al. | Melatonin alleviates cognition impairment by antagonizing brain insulin resistance in aged rats fed a high‐fat diet | |
| Tempfer et al. | A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis | |
| JP2016513640A5 (cg-RX-API-DMAC7.html) | ||
| Liu et al. | Activation of the unfolded protein response via inhibition of protein disulfide isomerase decreases the capacity for DNA repair to sensitize glioblastoma to radiotherapy | |
| MX2011008748A (es) | El status de expresion de msh3 determina la sensibilidad de celulas de cancer al tratamiento quimioterapeutico con inhibidores de parp y farmacos de platino. | |
| CY1122143T1 (el) | Φαρμακευτικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της b-raf, εναν αναστολεα του egfr και προαιρετικα εναν αναστολεα της ρι3κ-αλφα | |
| WO2014172376A3 (en) | Markers of tumor cell response to anti-cancer therapy | |
| WO2011133668A3 (en) | Methods and compositions for the treatment of cancer | |
| WO2016201450A3 (en) | Cancer treatment and diagnosis | |
| Familtseva et al. | Toll-like receptor 4 mutation suppresses hyperhomocysteinemia-induced hypertension | |
| Nakagawa et al. | Chronic kidney disease accelerates cognitive impairment in a mouse model of Alzheimer's disease, through angiotensin II | |
| Li et al. | Fisetin administration improves LPS-induced acute otitis media in mouse in vivo | |
| WO2013071012A3 (en) | Personalized strategic cancer treatment | |
| Fluitt et al. | To the future: the role of exosome‐derived microRNAs as markers, mediators, and therapies for endothelial dysfunction in type 2 diabetes mellitus | |
| Jung et al. | EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI | |
| Casey et al. | Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab | |
| Singh et al. | Idiopathic pulmonary fibrosis: where do we stand and how far to go | |
| NZ754328A (en) | Marker for acid sphingomyelinase disorders and uses thereof | |
| Blázquez-Prieto et al. | Exposure to mechanical ventilation promotes tolerance to ventilator-induced lung injury by Ccl3 downregulation | |
| Alhuneafat et al. | Cancer and cardiovascular disease: shared risk factors, mechanisms, and clinical implications: JACC: CardioOncology State-of-the-Art Review | |
| Wu et al. | Thoracic radiotherapy may improve the outcome of extensive stage small cell lung carcinoma patients treated with first-line immunotherapy plus chemotherapy | |
| Wang et al. | Beneficial therapeutic effects of hemoperfusion in the treatment of severe Stevens-Johnson syndrome/toxic epidermal necrolysis: preliminary results. |